→Boston-based Silicon Therapeutics has recruited Sanofi’s US cancer R&D chief Christopher Winter to come over and run the R&D side of the business. Silicon has advanced new tech focused on physics-based simulations, chemistry and disease biology. This is just the latest in a long lineup of pharma investigators making their way to the biotech world.
→ Syndax $SNDX CEO Briggs Morrison has in-licensed a portfolio of preclinical, oral small molecule inhibitors of the interaction of menin with the mixed lineage leukemia protein from Vitae, a subsidiary of Allergan.
→ Four months after Neothetics $NEOT was forced to read last rites over its sole experimental drug, the biotech is offering a convenient shell for a reverse merger into the market for Evofem Biosciences. An investor is buying $20 million in shares as Evofem pursues a late-stage study for a vaginal contraceptive.
→ Chi-Med and AstraZeneca are touting some preliminary partial responses from their early-stage work on combos using Tagrisso and Iressa with the experimental c-MET drug savolitinib.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 25,000+ biopharma pros who read Endpoints News by email every day.Free Subscription